EP0840622A4 - ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY - Google Patents

ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY

Info

Publication number
EP0840622A4
EP0840622A4 EP96924646A EP96924646A EP0840622A4 EP 0840622 A4 EP0840622 A4 EP 0840622A4 EP 96924646 A EP96924646 A EP 96924646A EP 96924646 A EP96924646 A EP 96924646A EP 0840622 A4 EP0840622 A4 EP 0840622A4
Authority
EP
European Patent Office
Prior art keywords
adeno
dendritic cells
associated viral
specific immunity
stimulate specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96924646A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0840622A1 (en
Inventor
Ramila Philip
Jane S Lebkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of EP0840622A1 publication Critical patent/EP0840622A1/en
Publication of EP0840622A4 publication Critical patent/EP0840622A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
EP96924646A 1995-07-21 1996-07-19 ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY Withdrawn EP0840622A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US566286 1983-12-28
US131295P 1995-07-21 1995-07-21
US1312 1995-07-21
US718495P 1995-11-01 1995-11-01
US7184 1995-11-01
US56628695A 1995-12-01 1995-12-01
PCT/US1996/012012 WO1997003703A1 (en) 1995-07-21 1996-07-19 Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity

Publications (2)

Publication Number Publication Date
EP0840622A1 EP0840622A1 (en) 1998-05-13
EP0840622A4 true EP0840622A4 (en) 2003-01-02

Family

ID=27356895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96924646A Withdrawn EP0840622A4 (en) 1995-07-21 1996-07-19 ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY

Country Status (5)

Country Link
EP (1) EP0840622A4 (ja)
JP (1) JPH11510046A (ja)
AU (1) AU6504596A (ja)
CA (1) CA2227065A1 (ja)
WO (1) WO1997003703A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
WO1997040182A1 (de) * 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
WO1999008713A1 (en) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
GB2370572B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd Use of a professional antigen presenting cell
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
WO2001027156A1 (en) * 1999-10-08 2001-04-19 Curagen Corporation Interleukin-2 like protein and nucleic acids encoding same
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
WO2006124700A2 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2008153802A1 (en) * 2007-05-29 2008-12-18 Eusa Pharma, Inc. Ex-vivo treatment of cancer using psma and antibodies thereto
CN110075113A (zh) 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
WO2013039989A1 (en) * 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP2015530413A (ja) 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
WO2018217989A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3837349A4 (en) * 2018-08-16 2022-06-08 The Regents of the University of California CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING FOR INDUCING THE PRODUCTION OF CELL VESICLES, MODIFICATIONS THEREOF AND USES THEREOF
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021287A1 (en) * 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
WO1995007995A2 (en) * 1993-09-13 1995-03-23 Applied Immune Sciences, Inc. Adeno-associated viral (aav) liposomes and methods related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021287A1 (en) * 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
WO1995007995A2 (en) * 1993-09-13 1995-03-23 Applied Immune Sciences, Inc. Adeno-associated viral (aav) liposomes and methods related thereto

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 40, no. 4, 1995, pages 268 - 271, ISSN: 0340-7004 *
CIBA FOUNDATION SYMPOSIUM, vol. 187, 1994, pages 97 - 112 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988, KOMATSUBARA S ET AL: "IMMORTALIZATION OF MURINE LEUKOCYTES BY ONCOGENES I. ATTEMPTS TO IMMORTALIZE SPLENIC DENDRITIC CELLS RESULTED IN THE PRODUCTION OF NONDENDRITIC TRANSFORMANT CELLS", XP002216735, Database accession no. PREV198987126604 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, YAMASAKI SEIJI ET AL: "Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.", XP002216737, Database accession no. PREV199598331808 *
DATABASE MEDLINE [online] "Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.", XP002216736, Database accession no. NLM7796678 *
MEMOIRS OF THE FACULTY OF SCIENCE KYOTO UNIVERSITY SERIES OF BIOLOGY, vol. 13, no. 1, 1988, pages 31 - 40, ISSN: 0454-7802 *
NAIR S ET AL: "SOLUBLE PROTEINS DELIVERED TO DENDRITIC CELLS VIA PH-SENSITIVE LIPOSOMES INDUCE PRIMARY CYTOTOXIC T LYMPHOCYTE RESPONSES IN VITRO", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 175, February 1992 (1992-02-01), pages 609 - 612, XP002910834, ISSN: 0022-1007 *
See also references of WO9703703A1 *
VRONIQUE FLAMAND ET AL: "Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, 1994, pages 605 - 610, XP002900616, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
WO1997003703A1 (en) 1997-02-06
AU6504596A (en) 1997-02-18
JPH11510046A (ja) 1999-09-07
EP0840622A1 (en) 1998-05-13
CA2227065A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
EP0840622A4 (en) ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
GB8923242D0 (en) Improvements in and relating to powered brushes
GB2303321B (en) Improvements in and relating to grinding
GB2301161B (en) Improvements in and relating to fixing
GB9412844D0 (en) Improvements in or relating to therapeutic methods
GB9502584D0 (en) Improvements in and relating to wwarf removal
GB9508494D0 (en) "Improvements in or relating to balloons"
GB2297781B (en) Improvements in or relating to posts
ZA966169B (en) Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
NZ293994A (en) Immortalized endothelial brain cell lines and their use in therapy
GB9421966D0 (en) Improvements in or relating to posts
GB2292690B (en) Improvements in and relating to training aids
GB2306093B (en) Improvements in and relating to fishing poles
EP0405931A3 (en) Improvements in and relating to anticonvulsant agents
GB2300528B (en) Improvements in and relating to electrical distribution
GB2202765B (en) Improvements in and relating to water conditioning
GB2305193B (en) Improvements in and relating to tents
GB2303080B (en) Improvements in or relating to plate separating devices
GB9401462D0 (en) Improvements in and relating to grinding
GB9516711D0 (en) Improvements in and relating to vortex drops
GB9506125D0 (en) Improvements in or relating to can crushers
GB8918686D0 (en) Improvements in and relating to building aids
GB8909445D0 (en) Improvements in and relating to umbrellas
GB9509692D0 (en) Improvements in and relating to unbalanced magnetrons
GB9513774D0 (en) Improvements in and relating to materials

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS PRODUCTS INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20021115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040611